Recombinant SARS-CoV-2 Nucleocapsid 抗体 (Whole Molecule)
Quick Overview for Recombinant SARS-CoV-2 Nucleocapsid 抗体 (Whole Molecule) (ABIN7581774)
抗原
See all SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) 抗体抗体类型
适用
宿主
克隆类型
标记
应用范围
质量等级
克隆位点
-
-
抗原表位
- Whole Molecule
-
Expression System
- Phage display
-
原理
- recombinant anti-SARS-CoV-2 Nucleocapsid protein antibody
-
特异性
- This is an antibody developed by antibody phage display technology using a human naive antibody gene library and SARS-CoV-2 antigen. For this antibody both the heavy and light chains are cloned and expressed, generating full-length antibodies.
-
交叉反应 （详细）
- SARS-CoV1 N-protein
-
产品特性
- This antibody can be detected with anti-mouse Fc secondary antibodies.
-
纯化方法
- Protein A purification
-
免疫原
- No immunization, animal-free antibody development. Antigen: Nucleocapsid protein: MSDNGPQSNQRSAPRITFGGPTDSTDNNQNGGRNGARPKQRRPQGLPNNTASWFTALTQHGKEELRFPRGQGVPINTNSGPDDQIGYYRRATRRVRGGDGKMKELSPRWYFYYLGTGPEASLPYGANKEGIVWVATEGALNTPKDHIGTRNPNNNAATVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRGNSRNSTPGSSRGNSPARMASGGGETALALLLLDRLNQLESKVSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKQYNVTQAFGRRGPEQTQGNFGDQDLIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYHGAIKLDDKDPQFKDNVILLNKHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADMDDFSRQLQNSMSGASADSTQA
-
亚型
- IgG2a
-
-
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibody
SARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, GICA 宿主: HEK-293 Cells Chimeric 1A6 unconjugated scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV) ELISA, IF 宿主: 兔 Chimeric CR3018 (03-018) unconjugated Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, IF 宿主: 小鼠 Monoclonal unconjugated
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, GICA 宿主: 小鼠 Monoclonal 3C6 unconjugated
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, GICA 宿主: Human Chimeric 1A6 unconjugated scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2), Virus ELISA, WB 宿主: 兔 Polyclonal unconjugated
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibody (HRP)SARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA 宿主: Human Monoclonal 1A6 HRP scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (C-Term) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) WB 宿主: 山羊 Polyclonal unconjugated
-
-
应用备注
- Western Blot: 0.2-5 μg/mL ELISA: 1-12 μg/mL as coating antibody 0.5-5 μg/mL as detection antibody IF: 0.1 - 10 μg/mL Optimal working dilution should be determined by the investigator
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- PBS, pH 7.4,
-
储存条件
- -20 °C
-
-
- SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
-
别名
- SARS-CoV-2 Nucleocapsid protein (NP)
-
背景
- Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that could inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.
-
分子量
- 25 kDa
-
NCBI登录号
- NP_828858
-
UniProt
- P59595
抗原
-
